Summary
This 8-K filing from Bristol-Myers Squibb (BMY) reports on a change within its Board of Directors. Effective July 21, 2017, Laurie H. Glimcher, M.D., will retire from her position on the Board. This retirement will also result in the Board's size being adjusted to ten directors.
Key Highlights
- 1Dr. Laurie H. Glimcher is retiring from the Bristol-Myers Squibb Board of Directors.
- 2Her retirement is effective July 21, 2017.
- 3The size of the Board of Directors will be reduced to ten members following Dr. Glimcher's departure.
Frequently Asked Questions
Dr. Laurie H. Glimcher is a member of the Bristol-Myers Squibb Board of Directors. Her departure, while a change in board composition, is a standard event. Investors should monitor future filings for any commentary on her replacement or strategic implications, if any.
Typically, a reduction in board size of this nature is a housekeeping matter and does not directly signal a change in company strategy or operations. The company's strategic direction is usually driven by executive management and communicated through other filings.
The board size will be set at ten directors concurrently with Dr. Glimcher's retirement, which is effective July 21, 2017.